Jazz Pharmaceuticals JAZZ PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's PP&E (net)?
- Jazz Pharmaceuticals (JAZZ) reported PP&E (net) of $203.1M in Q1 2026.
- How has Jazz Pharmaceuticals's PP&E (net) changed year-over-year?
- Jazz Pharmaceuticals's PP&E (net) increased by 13.5% year-over-year, from $178.87M to $203.1M.
- What is the long-term trend for Jazz Pharmaceuticals's PP&E (net)?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's PP&E (net) has grown at a 9.3% compound annual growth rate (CAGR), from $127.94M to $199.9M.
- What does PP&E (net) mean?
- The value of the company's physical assets like buildings and machinery, minus wear and tear.
- How do you interpret PP&E (net)?
- An increase suggests capital investment in infrastructure, while a decrease reflects depreciation or asset divestiture.
- How does PP&E (net) compare across companies?
- Varies significantly based on whether a company is a manufacturer or outsources production to contract manufacturers.